The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM . With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of ⩾ 0.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P o0.0002, respectively) and PFS ( 5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P o0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR) = 0.56, 95% CI, 0.32-0.96, P o 0.03) and OS (HR = 0.34, 95% CI, 0.16-0.68, P o 0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.
INTRODUCTION
The current hypothesis to support the survival benefit after autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) relied solely on the high-dose chemotherapy eradicating tumor cells. 1, 2 However, recent findings suggesting faster recovery of absolute lymphocyte counts at day 15 (ALC-15) after APBHSCT, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] as a prognostic factor of survival, have broadened our understanding of how APBHSCT improves clinical outcomes.
Our group first reported that ALC-15 recovery depends on the amount of infused autograft absolute lymphocyte count (A-ALC), and an infused A-ALC of ⩾ 0.5 × 10 9 cells/kg correlated with better survival after APBHSCT. 15, 16 An independent group has subsequently confirmed this finding. 17 In a randomized, double-blind, phase III clinical trial, patients infused with a higher A-ALC dose experienced superior survival after APBHSCT. 18 In a prospective study, the recovery of natural killer cells at day 15 (NKC-15) improved survival post APBHSCT. 19 Subsequently, an independent group confirmed the association between NK cell recovery and survival post APBHSCT. 20 From our randomized, double-blind, phase III clinical trial, the infusion of autograft natural killer cells (A-NKC) affected survival post APBHSCT. 18 These discoveries further solidify the hypothesis that innate immunity (that is, A-NKC and NKC-15) plays a vital role on survival in APBHSCT. 18, 19 Recent studies have shown that the development of myeloid-derived suppressor cells (that is, monocytic CD14 + HLA − DR low/neg ) 21 are recruited and transformed into tumor-associated macrophages by the tumor, affecting survival in cancer patients. 22 Two recent studies reported that circulating CD14 + HLA − DR low/neg monocytes were associated with poor prognosis in non-Hodgkin's lymphoma (NHL) patients. 23 , 24 Based on these findings we sought to evaluate whether the A-NKC/A-CD14+HLA-DR DIM ratio predicts survival in NHL patients undergoing APBHSCT.
MATERIALS AND METHODS

Patient population
Out of 122 patients who participated in our double-blind, phase III, randomized clinical trial, 111 were included in this study. 18 Of the 122 patients, 1 patient withdrew consent before starting treatment, 9 patients did not provide enough stem cells to proceed to transplant and one patient progressed during stem cell collection, leaving 111 patients who finished the double-blind, phase III, randomized clinical trial.
End points
The primary end point of this study was to assess the impact of A-NKC/A-CD14 + HLA-DR DIM ratio on overall survival (OS) and PFS. A secondary end point was to determine whether the A-NKC/A-CD14 + HLA-DR DIM ratio is an independent prognostic factor for OS and PFS.
Prognostic factors
The prognostic factors evaluated in this study included: international prognostic index (IPI) 25 at diagnosis (⩾2), age at diagnosis (⩾60 versus o60 years), lactate dehydrogenase at diagnosis (4normal), ECOG (Eastern Cooperative Oncology Group) performance status at diagnosis (41 versus ⩽ 1), extranodal sites at diagnosis (41 versus ⩽ 1), stage at diagnosis (III/IV versus I/II), histologies at diagnosis (diffuse large B-cell lymphoma versus others), disease status before APBHSCT (CR versus PR), infused CD34 + cell count, Plerixafor use and A-NKC/A-CD14 + HLA-DR DIM ratio.
PBSC (autograft) collection
Double-blind, randomized, phase III clinical trial was designed to assess whether the PFS was significantly increased among those patients whose apheresis was done using a modification to a standard Fenwal Amicus setting where mononuclear cell offset = 1.5 and RBC = 6.0 compared with where settings were mononuclear cells = 1.5 and RBC = 5.0. For stem cell mobilization, patients received 10 μg/kg of G-CSF SC daily for 5 to 7 consecutive days alone or in conjunction with 0.24 mg/kg of Plerixafor for up to 4 consecutive days by SC injection. Patients started with G-CSF and after 4 days of treatment, if the peripheral blood CD34 + count was 10 cells/μL, stem cell collection began. If the peripheral blood CD34 + count was 10 cells/μL, Plerixafor was added that evening and collections were initiated the next day. Apheresis collections were to be performed daily, with a goal of at least 2 × 10 6 CD34 + cells/kg. Additional collections were at the discretion of the transplantation team. For patients who failed mobilization or did not collect at least 2 × 10 6 CD34 + cells/kg, they were allowed to choose to either undergo a second mobilization/apheresis or discontinue study participation. Response and survival OS was measured from the date of APBHSCT to the date of death or last follow-up. 26 PFS was defined as the time from APBHSCT to time of progression, relapse, death or last follow-up. 26 Autograft lymphocyte and monocyte subset analysis Previously frozen autograft mononuclear cells (0.5-1.0 × 10 6 cells/mL) were thawed and aliquoted into 96-well round-bottomed plates (100 mL/well). The following monoclonal antibodies were used for autograft mononuclear cell immunophenotyping by flow cytometry: anti-human CD3 FITC, anti-human CD16 phycoerythrin (PE), anti-human CD56 PE for NK cells and anti-human CD14 FITC and anti-human HLA-DR PE-cyanin 5.5 (PE-Cy5.5) for HLA-DR dim monocytes (BD Pharmingen, San Jose, CA, USA). The desired antibody or antibody pool was added at 5 μL of each antibody/well. The cells and antibodies were incubated for 30 min at 4°C and washed twice with 1 × PBS (Cellgro, Manassas, VA, USA), 0.1% BSA and 0.05% sodium Abbreviations: IPI = International Prognostic Index; LDH = lactate dehydrogenase; ModC = modified apheresis machine; StdC = standard apheresis machine.
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Statistical analysis
OS and PFS were analyzed using the approach of Kaplan-Meier. 27 Differences between survival curves were tested for statistical significance using the two-tailed log-rank test.
Univariate and multivariate analysis was performed using Cox proportional hazard model. 28 We evaluated the variables in the prognostic factor section to assess their impact on OS and PFS times post APBHSCT. The choice of the cutoff value for the A-NKC/A-CD14 + HLA-DR DIM ratio to assess survival was based on its utility as a marker for the clinically relevant binary outcome of death/survival using the receiver operating characteristics curves (ROC) and area under the curve (AUC). The binary clinical outcome (death/survival) was established at 5 years after APHSCT. Patients were classified as 'alive/censored' when follow-up time was 45 years and 'death/uncensored' for patients known to have died before this time point. 29 A K-fold cross-validation with K-values of 10 was performed to validate the results of A-NKC/A-CD14 + HLA-DR DIM ratio cutoff obtained by the ROC and AUC curves. Randomly chosen subsets containing 90% of the cohort were used for training, and the remaining 10% were left for testing. The cross-validation process was then repeated 10 times. Based on this analysis, cross-validation AUC by the ROC was produced, representing the discriminating accuracy of A-NKC/A-CD14 + HLA-DR DIM ratio for the binary clinical outcomes of death/ survival.
The χ 2 tests and Fisher's exact tests were used to determine relationships between categorical variables as appropriate. The Wilcoxon rank test was used to determine associations between continuous variables and categories and nonparametric tests were used to evaluate associations for continuous variables. All P-values represented were two sided and statistical significance was declared at P o0.05.
RESULTS
Patient characteristics
The median age at the time of APBHSCT was 57 years (range: 20-74). The distribution of additional baseline characteristics for this cohort is presented in Table 1 . The median follow-up from APHSCT was 57.2 months (range: 2.1-84.6 months) and 62.6 months (range: 37.6-84.6 months) for patients who were alive (n = 72). The day-100 transplantation-related mortality was 1.8% (2/111): one patient died because of septic shock and one patient died of acute respiratory distress syndrome. Other than the 2 patients who died in the first ; A-NKC = autograft natural killer cell; CI = confidence interval; DLBCL = diffuse large B-cell lymphoma; HR = hazard ratio; IPI = International Prognostic Index; LDH = lactate dehydrogenase. ; A-NKC = autograft natural killer cell; CI = confidence interval; DLBCL = diffuse large B-cell lymphoma; HR = hazard ratio; IPI = International Prognostic Index; LDH = lactate dehydrogenase. + HLA-DR DIM ratio ⩾ 0.29 was a predictor for OS and PFS (see Table 2 Table 3 showed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent prognostic factor for OS (HR = 0.34, 95% CI, 0.16-0.68, P o0.002) and for PFS (HR = 0.56, 95% CI, 0.32-0.96, Po 0.03). Showing that A-NKC/A-CD14 + HLA-DR DIM ratio is a prognostic factor for survival, we categorized the patients into two groups (A-NKC/A-CD14 + HLA-DR DIM ratio ⩾ 0.29 versus A-NKC/A-CD14 + HLA-DR DIM ratio o 0.29) to assess whether both groups were balanced with regard to the baseline patient characteristics. Table 4 showed that both groups were balanced, except for lactate dehydrogenase, the disease status before APBHSCT and for the use of Plerixafor. 
DISCUSSION
The discovery of the correlation between the infusion of A-ALC and ALC-15 recovery and their association with survival post APBHSCT argues in favor of viewing the autograft content not merely to achieve hematopoietic recovery, but also to achieve immunologic recovery with direct impact on survival post APBHSCT. 30 The infusion of autograft dendritic cells, CD4 + and CD8 + T cells and NKCs have been reported to affect survival post 
